Is Big Pharma squandering its cash on buybacks?

Cash-rich pharma giants have been plowing billions of dollars into stock buybacks, making investors and Wall Street happy. But are buybacks the best use for Big Pharma's cash? Atlas Venture Partner Bruce Booth favors other ways to put those billions to work--ways that could deliver bigger returns in the long run. Report